Features of lipid metabolism in patients with type 2 diabetes mellitus and gout

Authors

DOI:

https://doi.org/10.15587/2519-4798.2024.306215

Keywords:

type 2 diabetes mellitus, gout, AMPK, chemerin, lipid metabolism

Abstract

The aim: To study the relationship between lipid metabolism parameters, chemerin, and adenosine monophosphate-activated protein kinase (AMPK) activity in patients with type 2 diabetes mellitus (T2DM), as well as in patients with a combined course of T2DM and gout.

Materials and methods. To assess lipid metabolism disorders, 100 patients were examined and divided into 2 groups: - 1st group – patients with T2DM and gout (n=70), 2nd group – patients with gout (n=30), control group (CG) - practically healthy individuals (n=20). The levels of total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and very low-density lipoprotein cholesterol (VLDL) were analyzed. As markers of insulin resistance (IR), the content of AMPK and chemerin was investigated. Statistical data processing was carried out using the statistical data processing program package version 8.0 STATISTICA (StatSoft Inc).

The results. A significant difference was found between the levels of lipid parameters (except HDL) when comparing patients with the combined pathology of T2DM and gout, with a monocourse of gout and representatives of CG (р<0.001). It was also found that among lipidogram indicators, in all groups, an inverse correlation of AMPK value with LDL level was found (strong for patients of the 1st group and medium strength for representatives of the 2nd group and CG). Another indicator with which AMPK levels in all groups were statistically reliably correlated was TC. The presence of a direct correlation between the levels of LDL and chemerin in the 2nd group and CG, as well as the levels of TC and chemerin in patients with a combination of T2DM with gout and an inverse correlation in the other groups (all p<0.05) was established.

Conclusions: Statistically significant relationships were found between lipid metabolism indicators, chemerin and AMPK activity in patients with T2DM, as well as in patients with combined course of T2DM and gout

Author Biography

Yuliia Stoianova, Kharkiv National Medical University

PhD Student

Department of Internal Medicine No3 and Endocrinology

References

  1. Ogurtsova, K., Guariguata, L., Barengo, N. C., Ruiz, P. L.-D., Sacre, J. W., Karuranga, S. et al. (2022). IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Research and Clinical Practice, 183, 109118. https://doi.org/10.1016/j.diabres.2021.109118
  2. Teck, J. (2022). Diabetes-Associated Comorbidities. Primary Care: Clinics in Office Practice, 49 (2), 275–286. https://doi.org/10.1016/j.pop.2021.11.004
  3. The Lancet Diabetes & Endocrinology. (2024). Undiagnosed type 2 diabetes: an invisible risk factor. The Lancet Diabetes & Endocrinology, 12 (4), 215. https://doi.org/10.1016/s2213-8587(24)00072-x
  4. Zheng, Y., Ley, S. H., Hu, F. B. (2017). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology, 14 (2), 88–98. https://doi.org/10.1038/nrendo.2017.151
  5. Levchuk, N. (2020). Biochemical and molecular mechanisms of the development of insulin resistance in adipose tissue cells. Endokrynologia, 25 (3), 243–250. https://doi.org/10.31793/1680-1466.2020.25-3.243
  6. Su, X., Cheng, Y., Zhang, G., Wang, B. (2021). Chemerin in inflammatory diseases. Clinica Chimica Acta, 517, 41–47. https://doi.org/10.1016/j.cca.2021.02.010
  7. Helfer, G., Wu, Q.-F. (2018). Chemerin: a multifaceted adipokine involved in metabolic disorders. Journal of Endocrinology, 238 (2), R79–R94. https://doi.org/10.1530/joe-18-0174
  8. Stojek, M. (2017). The role of chemerin in human disease. Postępy Higieny i Medycyny Doświadczalnej, 71 (1), 110–117. https://doi.org/10.5604/01.3001.0010.3795
  9. Buechler, C., Feder, S., Haberl, E., Aslanidis, C. (2019). Chemerin Isoforms and Activity in Obesity. International Journal of Molecular Sciences, 20 (5), 1128. https://doi.org/10.3390/ijms20051128
  10. Entezari, M., Hashemi, D., Taheriazam, A., Zabolian, A., Mohammadi, S., Fakhri, F. et al. (2022). AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation. Biomedicine & Pharmacotherapy, 146, 112563. https://doi.org/10.1016/j.biopha.2021.112563
  11. Herzig, S., Shaw, R. J. (2017). AMPK: guardian of metabolism and mitochondrial homeostasis. Nature Reviews Molecular Cell Biology, 19 (2), 121–135. https://doi.org/10.1038/nrm.2017.95
  12. Lin, S., Hardie, D. (2018). AMPK: Sensing Glucose as well as Cellular Energy Status. Cell Metabolism, 27 (2), 299–313. https://doi.org/10.1016/j.cmet.2017.10.009
  13. Madhavi, Y. V., Gaikwad, N., Yerra, V. G., Kalvala, A. K., Nanduri, S., Kumar, A. (2019). Targeting AMPK in Diabetes and Diabetic Complications: Energy Homeostasis, Autophagy and Mitochondrial Health. Current Medicinal Chemistry, 26 (27), 5207–5229. https://doi.org/10.2174/0929867325666180406120051
  14. AL-Husaini, F., Hywar, F., Elias, N., Falih, I. (2022). Evaluation of Chemerin in Diabetic Type 2 Patients with Metabolic Syndrome in both Gender. Iranian Journal of War & Public Health, 14 (4), 409–414.
  15. Kumari, R., Kumar, S., Kant, R. (2019). An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetology & Metabolic Syndrome, 13 (4), 2409–2417.
  16. Yue, G., An, Q., Xu, X., Jin, Z., Ding, J., Hu, Y. et al. (2023). The role of Chemerin in human diseases. Cytokine, 162, 156089. https://doi.org/10.1016/j.cyto.2022.156089
  17. Steinberg, G. R., Hardie, D. G. (2022). New insights into activation and function of the AMPK. Nature Reviews Molecular Cell Biology, 24 (4), 255–272. https://doi.org/10.1038/s41580-022-00547-x
  18. He, L., Zhou, X., Huang, N., Li, H., Tian, J., Li, T. et al. (2017). AMPK Regulation of Glucose, Lipid and Protein Metabolism: Mechanisms and Nutritional Significance. Current Protein & Peptide Science, 18 (6), 562–570. https://doi.org/10.2174/1389203717666160627071125

Downloads

Published

2024-07-16

How to Cite

Stoianova, Y. (2024). Features of lipid metabolism in patients with type 2 diabetes mellitus and gout . ScienceRise: Medical Science, (2(59), 14–17. https://doi.org/10.15587/2519-4798.2024.306215

Issue

No. 2(59) (2024)

Section

Medical Science

License

Copyright (c) 2024 Yuliia Stoianova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.